Azurocidin 蛋白, Human (HEK293, His)

Azurocidin Protein, Human (HEK293, His), a recombinant human Azurocidin produced in HEK293 cells, has a His tag. Azurocidin is a protein that is mobilized rapidly from emigrating polymorphonuclear leukocytes (PMN). Azurocidin serves as an important mediator during the initiation of the immune response^[1].

Azurocidin 从 PMN 分泌囊泡或初级颗粒中释放，充当单核细胞和巨噬细胞的趋化剂和激活剂。其功能结果是细胞因子释放和细菌吞噬作用增强，从而更有效地清除细菌。Azurocidin 激活白细胞是通过 β2-整合素介导的，Azurocidin 诱导的趋化性依赖于甲酰肽受体。此外，Azurocidin 激活内皮细胞，导致血管渗漏和水肿形成。由于这些原因，靶向 azurocidin 的释放及其作用可能对炎症性疾病具有治疗潜力^[1]。

Measured by its ability to enhance LPS-induced TNF-alpha secretion from THP-1 cells. The ED₅₀ for this effect is ≤1.315 μg/mL in the presence of 2 μg/mL LPS.

• 
  Measured by its ability to enhance LPS-induced TNF-alpha secretion from THP-1 cells. The ED₅₀ for this effect is 1.061 μg/mL in the presence of 2 μg/mL LPS, corresponding to a specific activity is 942.507 U/mg.

Human

HEK293

C-6*His

P20160 (I27-P250)

566  [NCBI]

IVGGRKARPRQFPFLASIQNQGRHFCGGALIHARFVMTAASCFQSQNPGVSTVVLGAYDLRRRERQSRQTFSISSMSENGYDPQQNLNDLMLLQLDREANLTSSVTILPLPLQNATVEAGTRCQVAGWGSQRSGGRLSRFPRFVNVTVTPEDQCRPNNVCTGVLTRRGGICNGDGGTPLVCEGLAHGVASFSLGPCGRGPDFFTRVALFRDWIDGVLNNPGPGP

Approximately 35-44 kDa due to the glycosylation.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized after extensive dialysis against 20 mM HEPES, 150 mM NaCl, pH 7.5 or PBS, pH 7.4, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Oliver Soehnlein, et al. Neutrophil-derived azurocidin alarms the immune system. J Leukoc Biol. 2009 Mar;85(3):344-51.  [Content Brief]